Statement from Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association on Recent Changes at FDA Office of Generic Drugs

Published Online: Thursday, March 14, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (March 14, 2013) — GPhA was disappointed to learn of Dr. Gregory Geba’s departure from the FDA’s Office of Generic Drugs (OGD). Today, 80% of prescriptions dispensed in America are generics. GPhA and its member companies rely on the strength and continuity of the OGD on critical matters such as regulations governing the entry to market of new, cost-saving generic versions of critical medicines, and the implementation of the GDUFA process.

As FDA Commissioner Margaret Hamburg said recently at the GPhA 2013 Annual Meeting, “There are few American households who have not benefited from the success of the generic drug industry. [The generic industry’s] task and our task is ensuring that the medications that these millions of Americans take every day are safe, effective and of high quality.”

We believe accomplishing this task requires a reliable, consistent, and properly-staffed regulatory partner. From 2010 to 2012, the Office of Generic Drugs had no leadership. Now, with Dr. Geba’s departure, we are significantly concerned about further disruption at the FDA. These vacancies and changes hold the potential to distract from the critical mission of the OGD, and slow the flow of information, guidance, and approvals needed to achieve an optimal generic drugs market for patients, payors, and the health care system.

We trust that FDA is doing everything possible to ensure that the Office of Generic Drugs is fully staffed so that it can continue its regulatory mandate and GDUFA implementation. We look forward to working with Dr. Janet Woodcock and others to strengthen OGD and ensure that patients have reliable access to safe and affordable generic medicines.

Related Articles
For many pharmacy organizations, the Supreme Court King v. Burwell decision upholding the Affordable Care Act’s tax subsidies fended off potential confusion for patients concerning health insurance.
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
Latest Issues
$auto_registration$